How to avoid another 'Vioxx'.
Frantz
Simon
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000209:etiology; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004345:Drug Industry; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards* / Q000639:trends; D035082:Federal Government; D005544:Forecasting; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000209:etiology; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000592:standards; D012306:Risk; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib